Introduction to Dual-Target Gene Therapy for Parkinson's Disease
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, and bradykinesia. Current standard of care, including levodopa therapy, becomes less effective over time and is associated with motor fluctuations and dyskinesias. Gene therapy has emerged as a promising strategy to restore dopamine synthesis in the striatum. However, previous approaches using adeno-associated virus (AAV) vectors to deliver a single gene, such as aromatic L-amino acid decarboxylase (AADC), still depend on exogenous levodopa. A dual-target approach that delivers both tyrosine hydroxylase (TH) and AADC could enable autonomous dopamine production, potentially reducing or eliminating the need for levodopa. This article reports the 12-month primary safety and tolerability outcomes of a multicenter, open-label, dose-escalation phase 1 trial evaluating BBM-P002, a novel AAV vector (AAVT42) co-delivering constitutively active TH and AADC.
Trial Design and Patient Population
The phase 1 trial enrolled ten participants with moderate-to-advanced Parkinson's disease across four dose cohorts. Participants received bilateral intraputaminal infusions of BBM-P002 at doses of 4.0 × 10^11 vg (Cohort 1; n=1), 6.0 × 10^11 vg (Cohort 2; n=2), 1.0 × 10^12 vg (Cohort 3; n=2), and 1.2 × 10^12 vg (Cohort 4; n=5). The primary outcome was safety and tolerability within 12 months post-treatment. Secondary outcomes included motor function assessments, but these are not the focus of this report. The trial was registered at ClinicalTrials.gov (NCT05822739) and conducted at multiple centers.
Safety and Tolerability Results
The trial achieved its primary outcome, demonstrating a favorable safety and tolerability profile. No dose-limiting toxicities or drug-related serious adverse events occurred. A total of 23 adverse events were reported, all judged by investigators to be unrelated to BBM-P002. These events were primarily mild and transient, including common post-surgical symptoms such as headache, nausea, and injection-site reactions. Importantly, systemic toxicity and clinically meaningful immunogenicity were absent. No patient withdrew due to adverse events. These results indicate that intraputaminal delivery of BBM-P002 is safe and well tolerated in this patient population.
Adverse Events Summary
- Total adverse events: 23
- Drug-related serious adverse events: 0
- Dose-limiting toxicities: 0
- Most events were mild and transient
- No systemic toxicity or clinically meaningful immunogenicity
Implications for Parkinson's Disease Treatment
The safety profile of BBM-P002 supports continued clinical development. The dual-target approach, co-delivering TH and AADC, has the potential to provide autonomous dopamine synthesis, which could reduce dependence on levodopa and improve motor fluctuations. However, efficacy data are not yet available; the phase 1 trial was designed primarily to assess safety. Future phase 2 trials will need to evaluate motor outcomes and biomarker changes. If successful, this gene therapy could represent a paradigm shift in PD management, offering a one-time treatment that restores endogenous dopamine production.
Comparison with Previous Gene Therapy Approaches
Previous AAV-mediated gene therapies for PD have focused on single genes, such as AADC or glial cell line-derived neurotrophic factor (GDNF). AADC monotherapy requires ongoing levodopa administration, as the enzyme converts levodopa to dopamine but does not synthesize dopamine from tyrosine. The dual-target approach addresses this limitation by including TH, the rate-limiting enzyme in dopamine synthesis. However, packaging two genes into a single AAV vector is challenging due to size constraints. The AAVT42 vector used in BBM-P002 was specifically designed to accommodate both TH and AADC. The favorable safety profile in this trial suggests that the vector is well tolerated and can effectively deliver both transgenes.
Future Directions
Based on these phase 1 results, the next steps include dose optimization and expansion to a larger patient population. The absence of immunogenicity is encouraging, as immune responses have been a concern in some gene therapy trials. Long-term follow-up will be necessary to assess durability of safety and potential efficacy. The trial investigators plan to report motor outcomes and biomarker data in future publications. If phase 2 trials confirm efficacy, BBM-P002 could become a leading candidate for disease-modifying therapy in Parkinson's disease.
Conclusion
This phase 1 trial demonstrates that intraputaminal delivery of BBM-P002, a dual-target gene therapy co-delivering TH and AADC, is safe and well tolerated in patients with moderate-to-advanced Parkinson's disease. The favorable safety profile supports continued clinical development. While efficacy remains to be proven, this approach holds promise for restoring autonomous dopamine synthesis and potentially reducing the burden of levodopa therapy. The results were published in Nature Medicine on June 10, 2026.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
